Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine

F. Villamil, G. Levy, G. L. Grazi, S. Mies, D. Samuel, F. Sanjuan, M. Rossi, J. Lake, S. Munn, F. Mühlbacher, L. Leonardi, U. Cillo

Research output: Contribution to journalArticlepeer-review


Choice of calcineurin inhibitor may be a contributing factor to deteriorating patient and graft survival following liver transplantation for hepatitis C virus (HCV). In our multicenter, open-label LIS2T study, de novo liver transplant patients stratified by HCV status were randomized to cyclosporine or tacrolimus. Follow-up data were obtained in an observational study of 95 patients. Mean follow-up was 34 and 37 months, respectively, for cyclosporine-treated (n = 47) and tacrolimus-treated (n = 48) patients. In patients not receiving antiviral therapy, 22 of 31 given cyclosporine (72%) and 24 of 29 given tacrolimus (83%) had biochemical recurrence of HCV. In 68 patients with at least one biopsy, histological evidence of HCV-related hepatitis was present in 27 of 31 (87%) cyclosporine-treated patients and 37 of 37 (100%) tacrolimus-treated patients (P = .02, chi-square test). Three-year actuarial risk of fibrosis stage 2 was 66% with cyclosporine and 90% with tacrolimus; for fibrosis stage 3 or 4 it was 46% and 80%, respectively. Three graft losses were attributed to HCV recurrence in cyclosporine-treated patients and six in tacrolimus-treated patients. Tacrolimus may be associated with increased risk of histological HCV disease recurrence compared to cyclosporine.

Original languageEnglish
Pages (from-to)2964-2967
Number of pages4
JournalTransplantation Proceedings
Issue number9
Publication statusPublished - Nov 2006

ASJC Scopus subject areas

  • Surgery
  • Transplantation


Dive into the research topics of 'Long-Term Outcomes in Liver Transplant Patients With Hepatic C Infection Receiving Tacrolimus or Cyclosporine'. Together they form a unique fingerprint.

Cite this